Evaluating the effect of melatonin compared to duloxetine in the treatment of chemotherapy-induced neuropathy (CINP): a clinical trial
Phase 3
Not yet recruiting
- Conditions
- Chemotherapy-induced neuropathy.Drug-induced polyneuropathyG62.0
- Registration Number
- IRCT20211028052893N1
- Lead Sponsor
- Babol University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Having solid cancer
age 15 to 75 years
receiving chemotherapy drugs
presence of sensory neuropathy symptoms
absence of neuropathy before starting chemotherapy
Exclusion Criteria
Diseases that cause sensory neuropathy such as diabetes
untreated hypothyroidism
sensitivity to medication (melatonin or duloxetine)
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method